{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T06:38:33Z","timestamp":1772087913700,"version":"3.50.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic cancer has a poor prognosis, with five-year survival rates of 10-13%. Surgery is the only curative option, though not feasible for many patients. Radiation therapy is crucial but limited by surrounding radiosensitive organs. Proton therapy provides improved dose distribution and higher biological effectiveness; however, clinical data comparing it to conventional photon therapy remains scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 41 patients with unresectable or recurrent pancreatic cancer treated with curative-intent proton therapy at Marburg Ion Beam Treatment Center. Median patient age was 69.5 years; 58.5% were male, 70.8% had T3\/4 tumors, and 73.2% presented at stage III. Median delivered dose was 54.0 GyE (median BED: 64.0 GyE) over 30 fractions. Most (95.1%) received proton therapy alone, 68.3% with concurrent chemotherapy. Outcomes evaluated included overall survival (OS), local recurrence-free survival (LRFS), progression-free survival (PFS), and CTCAE v5.0-assessed toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Proton therapy showed good tolerability with minimal toxicity (early grade \u2265III: 2.4%; late grade III: 4.9%, no late grade IV\/V). Local recurrence occurred in 13 patients (all within 6 months), and overall progression was noted in 33 patients (mostly within 1 year). Salvage RT correlated with worse PFS on univariate analysis (p=0.03), though non-significant in Cox regression (p=0.06). Adjuvant chemotherapy showed a non-significant trend toward improved OS (HR = 0.53, p=0.08). No dose-related factors influenced local recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Proton therapy for pancreatic cancer was well tolerated, though outcomes remained modest compared to recent studies utilizing higher doses and optimized protocols. Low toxicity supports proton therapy\u2019s theoretical advantages. Dose escalation and protocol optimization may enhance outcomes. Prospective studies with larger cohorts are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1710943","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:30:04Z","timestamp":1772083804000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Proton therapy for pancreatic cancer: real-world single-center experience of efficacy, toxicity, and predictors of outcome"],"prefix":"10.3389","volume":"16","author":[{"given":"Philipp","family":"Lishewski","sequence":"first","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, Marburg University Hospital","place":["Marburg, Germany"]},{"name":"Department of Radiotherapy and Radiation Oncology, Philipps University Marburg","place":["Marburg, Germany"]},{"name":"Marburg Ion-Beam Therapy Center (MIT), Department of Radiotherapy and Radiation Oncology, Marburg University Hospital","place":["Marburg, Germany"]},{"name":"Department of Radiotherapy and Radiation Oncology, University Cancer Center (UCT) Frankfurt \u2013 Marburg","place":["Marburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zelal","family":"Geyik","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, Philipps University Marburg","place":["Marburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Agolli","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Justus-Liebig-University Giessen, University Hospital","place":["Giessen, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerem Tuna","family":"Tas","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, Marburg University Hospital","place":["Marburg, Germany"]},{"name":"Department of Radiotherapy and Radiation Oncology, Philipps University Marburg","place":["Marburg, Germany"]},{"name":"Marburg Ion-Beam Therapy Center (MIT), Department of Radiotherapy and Radiation Oncology, Marburg University Hospital","place":["Marburg, Germany"]},{"name":"Department of Radiotherapy and Radiation Oncology, University Cancer Center (UCT) Frankfurt \u2013 Marburg","place":["Marburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houmam","family":"Anees","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, Marburg University Hospital","place":["Marburg, Germany"]},{"name":"Department of Trauma, Hand and Reconstructive Surgery, University Hospital Giessen and Marburg","place":["Giessen, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klemens","family":"Zink","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, Marburg University Hospital","place":["Marburg, Germany"]},{"name":"Marburg Ion-Beam Therapy Center (MIT), Department of Radiotherapy and Radiation Oncology, Marburg University Hospital","place":["Marburg, Germany"]},{"name":"Department of Radiotherapy and Radiation Oncology, University Cancer Center (UCT) Frankfurt \u2013 Marburg","place":["Marburg, Germany"]},{"name":"State offensive for the development of scientific and economic excellence (LOEWE) Research Cluster for Advanced Medical Physics in Imaging and Therapy, (ADMIT), University of Applied Science (TH) Mittel Hessen University of Applied Sciences","place":["Giessen, Germany"]},{"name":"Institute of Medical Physics and Radiation Protection, University of Applied Sciences","place":["Giessen, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Eberle","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, Marburg University Hospital","place":["Marburg, Germany"]},{"name":"Department of Radiotherapy and Radiation Oncology, Philipps University Marburg","place":["Marburg, Germany"]},{"name":"Marburg Ion-Beam Therapy Center (MIT), Department of Radiotherapy and Radiation Oncology, Marburg University Hospital","place":["Marburg, Germany"]},{"name":"Department of Radiotherapy and Radiation Oncology, University Cancer Center (UCT) Frankfurt \u2013 Marburg","place":["Marburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Rinke","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, University Cancer Center (UCT) Frankfurt \u2013 Marburg","place":["Marburg, Germany"]},{"name":"Department of Gastroenterology and Endocrinology, Philipps University Marburg","place":["Marburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilke","family":"Vorwerk","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, Marburg University Hospital","place":["Marburg, Germany"]},{"name":"Department of Radiotherapy and Radiation Oncology, Philipps University Marburg","place":["Marburg, Germany"]},{"name":"Marburg Ion-Beam Therapy Center (MIT), Department of Radiotherapy and Radiation Oncology, Marburg University Hospital","place":["Marburg, Germany"]},{"name":"Department of Radiotherapy and Radiation Oncology, University Cancer Center (UCT) Frankfurt \u2013 Marburg","place":["Marburg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Held","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital","place":["Heidelberg, Germany"]},{"name":"National Center for Tumor Diseases (NCT), NCT Heidelberg, a Partnership between German Cancer Research Center (DKFZ) and University Medical Center Heidelberg","place":["Heidelberg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Habermehl","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Justus-Liebig-University Giessen, University Hospital","place":["Giessen, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Adeberg","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, Marburg University Hospital","place":["Marburg, Germany"]},{"name":"Department of Radiotherapy and Radiation Oncology, Philipps University Marburg","place":["Marburg, Germany"]},{"name":"Marburg Ion-Beam Therapy Center (MIT), Department of Radiotherapy and Radiation Oncology, Marburg University Hospital","place":["Marburg, Germany"]},{"name":"Department of Radiotherapy and Radiation Oncology, University Cancer Center (UCT) Frankfurt \u2013 Marburg","place":["Marburg, Germany"]},{"name":"State offensive for the development of scientific and economic excellence (LOEWE) Research Cluster for Advanced Medical Physics in Imaging and Therapy, (ADMIT), University of Applied Science (TH) Mittel Hessen University of Applied Sciences","place":["Giessen, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Gawish","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, Marburg University Hospital","place":["Marburg, Germany"]},{"name":"Department of Radiotherapy and Radiation Oncology, Philipps University Marburg","place":["Marburg, Germany"]},{"name":"Marburg Ion-Beam Therapy Center (MIT), Department of Radiotherapy and Radiation Oncology, Marburg University Hospital","place":["Marburg, Germany"]},{"name":"Department of Radiotherapy and Radiation Oncology, University Cancer Center (UCT) Frankfurt \u2013 Marburg","place":["Marburg, Germany"]},{"name":"State offensive for the development of scientific and economic excellence (LOEWE) Research Cluster for Advanced Medical Physics in Imaging and Therapy, (ADMIT), University of Applied Science (TH) Mittel Hessen University of Applied Sciences","place":["Giessen, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"B1","article-title":"Cancer of the pancreas - cancer stat facts","volume-title":"Verf\u00fcgbar unter","year":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol November"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.10870","article-title":"Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer","volume":"105","author":"Versteijne","year":"2018","journal-title":"Br J Surg"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3390\/jcm9041129","article-title":"Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomized controlled trials","volume":"9","author":"Cloyd","year":"2020","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: A randomized clinical trial","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.7657","article-title":"Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study","volume":"32","author":"Valle","year":"2014","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870615)59:12<2006::AID-CNCR2820591206>3.0.CO;2-B","article-title":"Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer","volume":"59","author":"Douglass","year":"1987","journal-title":"Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1097\/00000658-199912000-00006","article-title":"Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group","volume":"230","author":"Klinkenbijl","year":"1999","journal-title":"Ann Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"S1323","DOI":"10.1016\/j.annonc.2023.10.084","article-title":"LBA83 Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial","volume":"34","author":"Koerkamp","year":"2023","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.12.003","article-title":"Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation","volume":"94","author":"Krishnan","year":"2016","journal-title":"Int J Radiat OncologyBiologyPhysics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/cancers10030075","article-title":"Stereotactic radiotherapy and particle therapy for pancreatic cancer","volume":"10","author":"Ng","year":"2018","journal-title":"Cancers. M\u00e4rz"},{"key":"B14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13014-015-0538-x","article-title":"Optimization of carbon ion and proton treatment plans using the raster-scanning technique for patients with unresectable pancreatic cancer","volume":"10","author":"Dreher","year":"2015","journal-title":"Radiat Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s13246-017-0540-8","article-title":"Relative biological effectiveness in a proton spread-out Bragg peak formed by pencil beam scanning mode","volume":"40","author":"Michaelidesov\u00e1","year":"2017","journal-title":"Australas Phys Eng Sci Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)02754-2","article-title":"Relative biological effectiveness (RBE) values for proton beam therapy","volume":"53","author":"Paganetti","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.radonc.2011.12.029","article-title":"A phase I\/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis","volume":"103","author":"Terashima","year":"2012","journal-title":"Radiotherapy Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1186\/s12885-020-07434-8","article-title":"Carbon ion radiotherapy as definitive treatment in non-metastasized pancreatic cancer: study protocol of the prospective phase II PACK-study","volume":"20","author":"Liermann","year":"2020","journal-title":"BMC Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1259\/bjr\/40226390","article-title":"The potential for mathematical modelling in the assessment of the radiation dose equivalent of cytotoxic chemotherapy given concomitantly with radiotherapy","volume":"78","author":"Jones","year":"2005","journal-title":"Br J Radiology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12553-024-00881-4","article-title":"Organization and operation of multi particle therapy facilities: the Marburg Ion-Beam Therapy Center, Germany (MIT)","volume":"14","author":"Zink","year":"2024","journal-title":"Health Technol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1016\/j.ijrobp.2018.06.250","article-title":"Estimation of the alpha-beta ratio for chemoradiation of locally advanced pancreatic cancer","volume":"102","author":"Prior","year":"2018","journal-title":"Int J Radiat Oncology Biology Physics"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2013.01.005","article-title":"Radiation dose responses for chemoradiation therapy of pancreatic cancer: An analysis of compiled clinical data using biophysical models","volume":"4","author":"Moraru","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.8904","article-title":"Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an eastern cooperative oncology group trial","volume":"29","author":"Loehrer","year":"2011","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.3446","article-title":"Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: A randomized EORTC-40013-22012\/FFCD-9203\/GERCOR phase II study","volume":"28","author":"Van Laethem","year":"2010","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"B26","unstructured":"Downloading IBM SPSS statistics 29\n          \n          2024"},{"key":"B27","volume-title":"Prism - graphPad","year":""},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/ckj\/sfs160","article-title":"The RIFLE and AKIN classifications for acute kidney injury: a critical and comprehensive review","volume":"6","author":"Lopes","year":"2013","journal-title":"Clin Kidney J"},{"key":"B30","unstructured":"Common terminology criteria for adverse events (CTCAE)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e0164473","DOI":"10.1371\/journal.pone.0164473","article-title":"Optimization of carbon ion treatment plans by integrating tissue specific \u03b1\/\u03b2-values for patients with non-resectable pancreatic cancer","volume":"11","author":"Dreher","year":"2016","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/1471-2407-13-419","article-title":"Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial","volume":"13","author":"Combs","year":"2013","journal-title":"BMC Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ijrobp.2024.12.020","article-title":"Proton beam therapy for pancreatic tumors: A consensus statement from the particle therapy cooperative group gastrointestinal subcommittee","volume":"122","author":"Chhabra","year":"2025","journal-title":"Int J Radiat OncologyBiologyPhysics"},{"key":"B34","doi-asserted-by":"publisher","first-page":"101577","DOI":"10.1016\/j.adro.2024.101577","article-title":"Clinical outcomes of proton beam therapy for unresectable locally advanced pancreatic cancer: A single-center retrospective study","volume":"9","author":"Seto","year":"2024","journal-title":"Adv Radiat Oncol Oktober"},{"key":"B35","doi-asserted-by":"publisher","first-page":"21712","DOI":"10.1038\/s41598-020-78875-1","article-title":"Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ctro.2020.12.001","article-title":"Dose-escalated simultaneously integrated boost photon or proton therapy in pancreatic cancer in an in-silico study: Gastrointestinal organs remain critical","volume":"27","author":"Stefanowicz","year":"2021","journal-title":"Clin Trans Radiat Oncol"},{"key":"B37","article-title":"Patient-specific modeling of dose-escalated proton beam therapy for locally advanced pancreatic cancer","author":"McIntyre","year":"2025","journal-title":"Verf\u00fcgbar"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-016-1057-x","article-title":"Simultaneous integrated protection: A new concept for high-precision radiation therapy","volume":"192","author":"Brunner","year":"2016","journal-title":"Strahlenther Onkol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.02.003","article-title":"Carbon-ion radiotherapy for locoregional recurrence after primary surgery for pancreatic cancer","volume":"129","author":"Kawashiro","year":"2018","journal-title":"Radiotherapy Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-021-01827-9","article-title":"Carbon ion radiotherapy as definitive treatment in locally recurrent pancreatic cancer","volume":"198","author":"Liermann","year":"2022","journal-title":"Strahlenther Onkol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-22-38","article-title":"Stereotactic body radiation therapy for the treatment of locally recurrent pancreatic cancer after surgical resection","volume":"13","author":"Reddy","year":"2022","journal-title":"J Gastrointest Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70021-4","article-title":"Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial","volume":"14","author":"Mukherjee","year":"2013","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0329","article-title":"Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: A phase 2 clinical trial","volume":"4","author":"Murphy","year":"2018","journal-title":"JAMA Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e35936","DOI":"10.1002\/cncr.35936","article-title":"A phase 1 dual-dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer","volume":"131","author":"Amit","year":"2025","journal-title":"Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1710943\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:30:07Z","timestamp":1772083807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1710943\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":44,"alternative-id":["10.3389\/fonc.2026.1710943"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1710943","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"article-number":"1710943"}}